← Back to Clinical Trials
Recruiting NCT06145984

NCT06145984 Mechanisms of Change of Positive Interventions in Reducing Vulnerability for Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06145984
Status Recruiting
Phase
Sponsor University Medical Center Groningen
Condition Depression in Remission
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2020-06-19
Primary Completion 2026-09-24

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
MindfulnessPositive Fantasizing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2020-06-19 with a primary completion date of 2026-09-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand the effects of mindfulness and fantasizing in reducing perseverative cognition underlying vulnerability for depression.

Eligibility Criteria

Inclusion Criteria: In order to be eligible to participate in this study, all participants must meet all the following criteria: * Participants should be between 18 and 60 years old. Participants should not exceed 60 years of age in order to minimize aging-related decline in information processing; * Participants should display normal intelligence (IQ\>85, as assessed with the Dutch Adult Reading Test and/or having finished an education on at least vocational level) in order to assure sufficient task comprehension. Participants in the remitted Major Depressive Disorder group should meet the following criteria to make sure that participants are at high risk of depressive relapse and currently show no clinically relevant severity of depressive symptoms: * Remitted participants should have experienced at least two depressive episodes, according to criteria defined by the Diagnostic Statistical Manual, version 5 (DSM-5), experienced in past ten years; * Remitted participants should score 21 or lower on the Inventory of Depressive Symptomatology (IDS-SR30), indicative of the absence of clinically relevant depressive symptoms. Exclusion Criteria: Furthermore, individuals who meet any of the following criteria will be excluded from participation in this study: * Fulfilling criteria for any current DSM-5 diagnosis as objectified with the Structured Clinical Interview for DSM-5 (SCID-5); * Daily use of anti-depressive medication, benzodiazepines, methylphenidate, beta blockers or other medication potentially influencing electrocardiogram currently or in the last four weeks; * Recent engagement (defined as in their last episode, or as one year prior to inclusion in case the last episode was more than a year before inclusion) in preventive cognitive therapy including the positive fantasizing technique and/or have recent experiences (defined as daily practice in the past two years for at least two weeks) with mindfulness, meditation, or mindful yoga. This criterion prevents underestimation of true effects of mindfulness and/or positive fantasizing and maximizes treatment effects; * Participation in another clinical intervention study at the moment of inclusion in the study to prevent overlapping intervention effects. Individuals for the Never-Depressed control group who additionally meet any of the following criteria will be excluded from participation of this study: * Presence of symptoms of depression according to the IDS-SR30 (score \> 13), to make sure participants are not currently experiencing clinically relevant depressive symptoms; * Any life-time psychopathology of any disorder as objectified with the SCID-5.

Contact & Investigator

Central Contact

Marie-José van Tol, professor

✉ m.j.van.tol@umcg.nl

📞 +31503616405

Principal Investigator

Marie-José van Tol, professor

PRINCIPAL INVESTIGATOR

University Medical Center Groningen

Frequently Asked Questions

Who can join the NCT06145984 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Depression in Remission. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06145984 currently recruiting?

Yes, NCT06145984 is actively recruiting participants. Contact the research team at m.j.van.tol@umcg.nl for enrollment information.

Where is the NCT06145984 trial being conducted?

This trial is being conducted at Groningen, Netherlands.

Who is sponsoring the NCT06145984 clinical trial?

NCT06145984 is sponsored by University Medical Center Groningen. The principal investigator is Marie-José van Tol, professor at University Medical Center Groningen. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology